These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders]. Baghdadli A; Gonnier V; Aussilloux C Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786 [TBL] [Abstract][Full Text] [Related]
3. Why have drug treatments been so disappointing? Buitelaar JK Novartis Found Symp; 2003; 251():235-44; discussion 245-9, 281-97. PubMed ID: 14521196 [TBL] [Abstract][Full Text] [Related]
4. Neurochemical correlates of autistic disorder: a review of the literature. Lam KS; Aman MG; Arnold LE Res Dev Disabil; 2006; 27(3):254-89. PubMed ID: 16002261 [TBL] [Abstract][Full Text] [Related]
5. Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder. Anderson GM Med Biol; 1987; 65(2-3):67-74. PubMed ID: 3309489 [TBL] [Abstract][Full Text] [Related]
6. Psychopharmacology in autism: an update. Canitano R; Scandurra V Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):18-28. PubMed ID: 21034789 [TBL] [Abstract][Full Text] [Related]
8. Risperidone: a potential treatment for autism. Posey DJ; McDougle CJ Curr Opin Investig Drugs; 2002 Aug; 3(8):1212-6. PubMed ID: 12211417 [TBL] [Abstract][Full Text] [Related]
9. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. Findling RL J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147 [TBL] [Abstract][Full Text] [Related]
10. Childhood autism: a circuit syndrome? Lee DA; Lopez-Alberola R; Bhattacharjee M Neurologist; 2003 Mar; 9(2):99-109. PubMed ID: 12808372 [TBL] [Abstract][Full Text] [Related]
11. Neurochemistry in the pathophysiology of autism. McDougle CJ; Erickson CA; Stigler KA; Posey DJ J Clin Psychiatry; 2005; 66 Suppl 10():9-18. PubMed ID: 16401145 [TBL] [Abstract][Full Text] [Related]
12. [Research on autism. Different aspects of changes observed during the development period]. Rothenberger A Encephale; 1992; 18(3):217-23. PubMed ID: 1299591 [TBL] [Abstract][Full Text] [Related]
13. Oxidative pathways as a drug target for the treatment of autism. Villagonzalo KA; Dodd S; Dean O; Gray K; Tonge B; Berk M Expert Opin Ther Targets; 2010 Dec; 14(12):1301-10. PubMed ID: 20954799 [TBL] [Abstract][Full Text] [Related]
14. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. Hampson DR; Adusei DC; Pacey LK Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634 [TBL] [Abstract][Full Text] [Related]
15. Developmental approaches to understanding and treating autism. Charman T Folia Phoniatr Logop; 2010; 62(4):166-77. PubMed ID: 20460929 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Leskovec TJ; Rowles BM; Findling RL Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882 [TBL] [Abstract][Full Text] [Related]
17. Role of risperidone in children with autism spectrum disorder. Chavez B; Chavez-Brown M; Rey JA Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811 [TBL] [Abstract][Full Text] [Related]
18. Neurofeedback for autistic spectrum disorder: a review of the literature. Coben R; Linden M; Myers TE Appl Psychophysiol Biofeedback; 2010 Mar; 35(1):83-105. PubMed ID: 19856096 [TBL] [Abstract][Full Text] [Related]
19. [Management of children with autism spectrum disorders]. Gadia CA; Tuchman RF Rev Neurol; 2003 Jan 16-31; 36(2):166-73. PubMed ID: 12589605 [TBL] [Abstract][Full Text] [Related]
20. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]